{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T01:10:29Z","timestamp":1789089029113,"version":"build-2803163510"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":77,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82100766"],"award-info":[{"award-number":["82100766"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82170745"],"award-info":[{"award-number":["82170745"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Research Fund of Shanghai Tongren Hospital, Shanghai Jiao Tong University School of Medicine","award":["TRKYRC-xx202206"],"award-info":[{"award-number":["TRKYRC-xx202206"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hyperuricemic nephropathy (HN) is a prevalent metabolic disorder characterized by tubulointerstitial inflammation and fibrosis, driven primarily by aberrant NLR family pyrin domain containing 3 (NLRP3) inflammasome activation. However, effective therapies targeting this pathogenic axis remain elusive. We aimed to identify a pharmacological intervention for HN and elucidate its mechanisms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A targeted phenotypic screen of natural phenolic compounds was conducted against uric acid (UA)-induced inflammasome responses. Multi-omics profiling, molecular docking, and multi-dimensional biophysical assays\u2014including surface plasmon resonance, cellular thermal shift assays, and circular dichroism\u2014and site-directed mutagenesis were utilized to identify and characterize the direct molecular target. The underlying post-translational regulatory mechanism was investigated through co-immunoprecipitation and ubiquitination assays. In vivo efficacy and short-term tolerability were evaluated in a rat model of HN. Clinical relevance was assessed via renal biopsies and clinical sample analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We identified\n                      <jats:italic>p<\/jats:italic>\n                      -coumaric acid (\n                      <jats:italic>p<\/jats:italic>\n                      -CA) as a potent pharmacological candidate. Mechanistically,\n                      <jats:italic>p<\/jats:italic>\n                      -CA engages the Cathepsin B (CTSB) active-site\/occluding-loop region, involving residues Cys26 and His110, and suppresses CTSB enzymatic activity. Notably, we uncovered a post-lysosomal regulatory model in which UA-induced lysosomal CTSB leakage is associated with a CTSB activity-associated reduction in WW domain-containing E3 ubiquitin protein ligase 1 (WWP1) protein abundance\/stability, thereby impairing WWP1-dependent K48-linked polyubiquitination and proteasomal clearance of NLRP3 and promoting inflammasome activation.\n                      <jats:italic>p<\/jats:italic>\n                      -CA-mediated CTSB inhibition preserves WWP1 protein abundance, restores NLRP3 proteasomal clearance, and attenuates downstream pyroptosis, inflammation, and fibrogenesis. CTSB knockdown attenuated the additional protective effect of\n                      <jats:italic>p<\/jats:italic>\n                      -CA, while pharmacological CTSB inhibition phenocopied\n                      <jats:italic>p<\/jats:italic>\n                      -CA, supporting CTSB pathway dependence. Furthermore, in vivo evaluations demonstrated that\n                      <jats:italic>p<\/jats:italic>\n                      -CA exerts urate-independent renoprotection without overt short-term systemic toxicities associated with synthetic CTSB inhibitors. Clinically, aberrant CTSB and NLRP3 upregulation correlated with impaired renal function in patients from the hyperuricemia-associated CKD cohort.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Our findings support the CTSB-WWP1-NLRP3 regulatory axis as a previously unrecognized pathogenic mechanism of HN, revealing how lysosomal damage drives inflammasome hyperactivation by disrupting ubiquitin-dependent clearance. The precise molecular mechanism linking CTSB activity to WWP1 turnover remains to be fully defined. Targeting CTSB with\n                      <jats:italic>p<\/jats:italic>\n                      -CA provides a promising prophylactic or co-treatment candidate for HN warranting further translational evaluation.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s10020-026-01544-y","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T05:54:27Z","timestamp":1782453267000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting Cathepsin B with p-coumaric acid rescues WWP1-dependent proteasomal degradation of NLRP3 in hyperuricemic nephropathy"],"prefix":"10.1186","volume":"32","author":[{"given":"Fengqin","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanzhe","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naijun","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiao","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuchu","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinmiao","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2148-0658","authenticated-orcid":false,"given":"Xiaoxia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"key":"1544_CR1","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.2174\/1389557521666210114163024","volume":"21","author":"MF Abazari","year":"2021","unstructured":"Abazari MF, Nasiri N, Karizi SZ, Nejati F, Haghi-Aminjan H, Norouzi S, et al. An updated review of various medicinal applications of p-coumaric acid: from antioxidative and anti-inflammatory properties to effects on cell cycle and proliferation. Mini Rev Med Chem. 2021;21:2187\u2013201.","journal-title":"Mini Rev Med Chem"},{"key":"1544_CR2","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1056\/NEJMoa1915833","volume":"382","author":"SV Badve","year":"2020","unstructured":"Badve SV, Pascoe EM, Tiku A, Boudville N, Brown FG, Cass A, et al. Effects of Allopurinol on the Progression of Chronic Kidney Disease. New Engl J Med. 2020;382:2504\u201313.","journal-title":"New Engl J Med"},{"key":"1544_CR3","doi-asserted-by":"publisher","first-page":"25970","DOI":"10.31083\/FBL25970","volume":"30","author":"S Beesetti","year":"2025","unstructured":"Beesetti S. Ubiquitin Ligases in Control: Regulating NLRP3 Inflammasome Activation. Front Biosci-Landmrk. 2025;30:25970.","journal-title":"Front Biosci-Landmrk"},{"key":"1544_CR4","doi-asserted-by":"publisher","first-page":"39884","DOI":"10.1038\/srep39884","volume":"7","author":"TT Braga","year":"2017","unstructured":"Braga TT, Forni MF, Correa-Costa M, Ramos RN, Barbuto JA, Branco P, et al. Soluble Uric Acid Activates the NLRP3 Inflammasome. Sci Rep-UK. 2017;7:39884.","journal-title":"Sci Rep-UK"},{"key":"1544_CR5","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.abb.2019.02.015","volume":"670","author":"RI Campden","year":"2019","unstructured":"Campden RI, Zhang Y. The role of lysosomal cysteine cathepsins in NLRP3 inflammasome activation. Arch Biochem BIOPHYS. 2019;670:32\u201342.","journal-title":"Arch Biochem BIOPHYS"},{"key":"1544_CR6","doi-asserted-by":"publisher","first-page":"416","DOI":"10.2174\/0115680266276823231230183519","volume":"24","author":"F Chen","year":"2024","unstructured":"Chen F, Zhang X, Wang J, Wang F, Mao J. P-coumaric Acid: Advances in Pharmacological Research Based on Oxidative Stress. Curr Top Med Chem. 2024;24:416\u201336.","journal-title":"Curr Top Med Chem"},{"key":"1544_CR7","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3389\/fcell.2017.00114","volume":"5","author":"P Cocchiaro","year":"2017","unstructured":"Cocchiaro P, De Pasquale V, Della MR, Tafuri S, Avallone L, Pizard A, et al. The Multifaceted Role of the Lysosomal Protease Cathepsins in Kidney Disease. Front Cell Dev Biol. 2017;5:114.","journal-title":"Front Cell Dev Biol"},{"key":"1544_CR8","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41589-019-0277-7","volume":"15","author":"RC Coll","year":"2019","unstructured":"Coll RC, Hill JR, Day CJ, Zamoshnikova A, Boucher D, Massey NL, et al. MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition. Nat Chem Biol. 2019;15:556\u20139.","journal-title":"Nat Chem Biol"},{"key":"1544_CR9","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/s41584-020-0441-1","volume":"16","author":"M Dehlin","year":"2020","unstructured":"Dehlin M, Jacobsson L, Roddy E. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat Rev Rheumatol. 2020;16:380\u201390.","journal-title":"Nat Rev Rheumatol"},{"key":"1544_CR10","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/imr.12286","volume":"265","author":"EI Elliott","year":"2015","unstructured":"Elliott EI, Sutterwala FS. Initiation and perpetuation of NLRP3 inflammasome activation and assembly. Immunol Rev. 2015;265:35\u201352.","journal-title":"Immunol Rev"},{"key":"1544_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.111324","volume":"127","author":"T Gao","year":"2024","unstructured":"Gao T, Wang T, Wu L, Tong Y, Tian J, Zhao K, et al. Saikosaponin-d alleviates depression by promoting NLRP3 ubiquitination and inhibiting inflammasome activation. Int Immunopharmacol. 2024;127:111324.","journal-title":"Int Immunopharmacol"},{"key":"1544_CR12","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1021\/jf053169a","volume":"54","author":"G Garrait","year":"2006","unstructured":"Garrait G, Jarrige JF, Blanquet S, Beyssac E, Cardot JM, Alric M. Gastrointestinal absorption and urinary excretion of trans-cinnamic and p-coumaric acids in rats. J Agr Food Chem. 2006;54:2944\u201350.","journal-title":"J Agr Food Chem"},{"key":"1544_CR13","doi-asserted-by":"publisher","first-page":"2876","DOI":"10.1038\/nprot.2006.202","volume":"1","author":"NJ Greenfield","year":"2006","unstructured":"Greenfield NJ. Using circular dichroism spectra to estimate protein secondary structure. Nat Protoc. 2006;1:2876\u201390.","journal-title":"Nat Protoc"},{"key":"1544_CR14","doi-asserted-by":"publisher","first-page":"364","DOI":"10.20452\/pamw.1821","volume":"123","author":"E Grzebyk","year":"2013","unstructured":"Grzebyk E, Knapik-Kordecka M, Piwowar A. Advanced glycation end-products and cathepsin cysteine protease in type 2 diabetic patients. Pol Arch Med Wewn. 2013;123:364\u201370.","journal-title":"Pol Arch Med Wewn"},{"key":"1544_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.858494","volume":"13","author":"Y Hu","year":"2022","unstructured":"Hu Y, Shi Y, Chen H, Tao M, Zhou X, Li J, et al. Blockade of Autophagy Prevents the Progression of Hyperuricemic Nephropathy Through Inhibiting NLRP3 Inflammasome-Mediated Pyroptosis. Front Immunol. 2022;13:858494.","journal-title":"Front Immunol"},{"key":"1544_CR16","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1038\/s41423-021-00740-6","volume":"18","author":"Y Huang","year":"2021","unstructured":"Huang Y, Xu W, Zhou R. NLRP3 inflammasome activation and cell death. Cell Mol Immunol. 2021;18:2114\u201327.","journal-title":"Cell Mol Immunol"},{"key":"1544_CR17","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s11926-016-0587-7","volume":"18","author":"D Hyndman","year":"2016","unstructured":"Hyndman D, Liu S, Miner JN. Urate Handling in the Human Body. Curr Rheumatol Rep. 2016;18:34.","journal-title":"Curr Rheumatol Rep"},{"key":"1544_CR18","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ejphar.2012.11.006","volume":"699","author":"RA Jyoti","year":"2013","unstructured":"Jyoti RA, Stanely MPP. Preventive effects of p-coumaric acid on lysosomal dysfunction and myocardial infarct size in experimentally induced myocardial infarction. Eur J Pharmacol. 2013;699:33\u20139.","journal-title":"Eur J Pharmacol"},{"key":"1544_CR19","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.semnephrol.2004.10.001","volume":"25","author":"DH Kang","year":"2005","unstructured":"Kang DH, Nakagawa T. Uric acid and chronic renal disease: possible implication of hyperuricemia on progression of renal disease. Semin Nephrol. 2005;25:43\u20139.","journal-title":"Semin Nephrol"},{"key":"1544_CR20","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1124\/pr.108.000992","volume":"62","author":"T Kenakin","year":"2010","unstructured":"Kenakin T, Miller LJ. Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol Rev. 2010;62:265\u2013304.","journal-title":"Pharmacol Rev"},{"key":"1544_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2020.105637","volume":"157","author":"M Kinra","year":"2021","unstructured":"Kinra M, Joseph A, Nampoothiri M, Arora D, Mudgal J. Inhibition of NLRP3-inflammasome mediated IL-1\u03b2 release by phenylpropanoic acid derivatives: in-silico and in-vitro approach. Eur J Pharm Sci. 2021;157:105637.","journal-title":"Eur J Pharm Sci"},{"key":"1544_CR22","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1021\/jf035366k","volume":"52","author":"Y Konishi","year":"2004","unstructured":"Konishi Y, Hitomi Y, Yoshioka E. Intestinal absorption of p-coumaric and gallic acids in rats after oral administration. J Agric Food Chem. 2004;52:2527\u201332.","journal-title":"J Agric Food Chem"},{"key":"1544_CR23","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/nri3452","volume":"13","author":"E Latz","year":"2013","unstructured":"Latz E, Xiao TS, Stutz A. Activation and regulation of the inflammasomes. Nat Rev Immunol. 2013;13:397\u2013411.","journal-title":"Nat Rev Immunol"},{"key":"1544_CR24","doi-asserted-by":"publisher","first-page":"111488","DOI":"10.1016\/j.yexcr.2019.07.001","volume":"383","author":"S Li","year":"2019","unstructured":"Li S, Lin Q, Shao X, Mou S, Gu L, Wang L, et al. NLRP3 inflammasome inhibition attenuates cisplatin-induced renal fibrosis by decreasing oxidative stress and inflammation. Exp Cell Res. 2019;383:111488.","journal-title":"Exp Cell Res"},{"key":"1544_CR25","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.2353\/ajpath.2008.080433","volume":"173","author":"SL Lin","year":"2008","unstructured":"Lin SL, Kisseleva T, Brenner DA, Duffield JS. Pericytes and perivascular fibroblasts are the primary source of collagen-producing cells in obstructive fibrosis of the kidney. Am J Pathol. 2008;173:1617\u201327.","journal-title":"Am J Pathol"},{"key":"1544_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-025-08303-5","volume":"8","author":"H Lin","year":"2025","unstructured":"Lin H, Nie L, Wu D, Zhang D, Peng R, Tao S, et al. Cathepsin B-dependent glycolysis contributes to reduced renal uric acid excretion in hyperuricemia. Commun Biol. 2025;8:845.","journal-title":"Commun Biol"},{"key":"1544_CR27","doi-asserted-by":"publisher","first-page":"2716","DOI":"10.1681\/ASN.2014080793","volume":"26","author":"N Liu","year":"2015","unstructured":"Liu N, Wang L, Yang T, Xiong C, Xu L, Shi Y, et al. EGF receptor inhibition alleviates hyperuricemic nephropathy. J Am Soc Nephrol. 2015;26:2716\u201329.","journal-title":"J Am Soc Nephrol"},{"key":"1544_CR28","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/febs.15118","volume":"287","author":"G Lopez-Castejon","year":"2020","unstructured":"Lopez-Castejon G. Control of the inflammasome by the ubiquitin system. FEBS J. 2020;287:11\u201326.","journal-title":"FEBS J"},{"key":"1544_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.911982","volume":"13","author":"JL Lu","year":"2022","unstructured":"Lu JL, Zeng XS, Zhou X, Yang JL, Ren LL, Long XY, et al. Molecular basis underlying hepatobiliary and renal excretion of phenolic acids of Salvia miltiorrhiza roots (Danshen). Front Pharmacol. 2022;13:911982.","journal-title":"Front Pharmacol"},{"key":"1544_CR30","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1053\/j.ajkd.2016.11.006","volume":"69","author":"MA Lusco","year":"2017","unstructured":"Lusco MA, Fogo AB, Najafian B, Alpers CE. AJKD atlas of renal pathology: gouty nephropathy. Am J Kidney Dis. 2017;69:e5\u20136.","journal-title":"Am J Kidney Dis"},{"key":"1544_CR31","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.1096\/fj.06-7924com","volume":"21","author":"SP Lutgens","year":"2007","unstructured":"Lutgens SP, Cleutjens KB, Daemen MJ, Heeneman S. Cathepsin cysteine proteases in cardiovascular disease. FASEB J. 2007;21:3029\u201341.","journal-title":"FASEB J"},{"key":"1544_CR32","doi-asserted-by":"publisher","first-page":"3696","DOI":"10.1021\/acs.jctc.5b00255","volume":"11","author":"JA Maier","year":"2015","unstructured":"Maier JA, Martinez C, Kasavajhala K, Wickstrom L, Hauser KE, Simmerling C. ff14SB: improving the accuracy of protein side chain and backbone parameters from ff99SB. J Chem Theory Comput. 2015;11:3696\u2013713.","journal-title":"J Chem Theory Comput"},{"key":"1544_CR33","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.2174\/0929866529666220426121324","volume":"22","author":"N Malik","year":"2022","unstructured":"Malik N, Dhiman P. New approaches and advancements in drug development from phenolic p-coumaric acid. Curr Top Med Chem. 2022;22:1515\u201329.","journal-title":"Curr Top Med Chem"},{"key":"1544_CR34","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/289734","volume":"2015","author":"L Musante","year":"2015","unstructured":"Musante L, Tataruch D, Gu D, Liu X, Forsblom C, Groop PH, et al. Proteases and protease inhibitors of urinary extracellular vesicles in diabetic nephropathy. J Diabetes Res. 2015;2015:289734.","journal-title":"J Diabetes Res"},{"key":"1544_CR35","doi-asserted-by":"publisher","first-page":"244","DOI":"10.3109\/0886022X.2013.835268","volume":"36","author":"D Navaneethan","year":"2014","unstructured":"Navaneethan D, Rasool M. p-Coumaric acid, a common dietary polyphenol, protects cadmium chloride-induced nephrotoxicity in rats. Ren Fail. 2014;36:244\u201351.","journal-title":"Ren Fail"},{"key":"1544_CR36","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1002\/biof.1377","volume":"43","author":"MK Neog","year":"2017","unstructured":"Neog MK, Joshua PS, Krishnan M, Rasool M. p-Coumaric acid, a dietary polyphenol ameliorates inflammation and curtails cartilage and bone erosion in the rheumatoid arthritis rat model. BioFactors. 2017;43:698\u2013717.","journal-title":"BioFactors"},{"key":"1544_CR37","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1021\/acs.jnatprod.9b01285","volume":"83","author":"DJ Newman","year":"2020","unstructured":"Newman DJ, Cragg GM. Natural Products as Sources of New Drugs over the Nearly Four Decades from 01\/1981 to 09\/2019. J Nat Prod. 2020;83:770\u2013803.","journal-title":"J Nat Prod"},{"key":"1544_CR38","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1038\/s41423-021-00670-3","volume":"18","author":"S Paik","year":"2021","unstructured":"Paik S, Kim JK, Silwal P, Sasakawa C, Jo EK. An update on the regulatory mechanisms of NLRP3 inflammasome activation. Cell Mol Immunol. 2021;18:1141\u201360.","journal-title":"Cell Mol Immunol"},{"key":"1544_CR39","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1080\/13543784.2018.1471133","volume":"27","author":"T Pascart","year":"2018","unstructured":"Pascart T, Richette P. Investigational drugs for hyperuricemia, an update on recent developments. Expert Opin Inv Drug. 2018;27:437\u201344.","journal-title":"Expert Opin Inv Drug"},{"key":"1544_CR40","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/S0014-5793(00)02337-1","volume":"487","author":"A Pavlova","year":"2000","unstructured":"Pavlova A, Krupa JC, Mort JS, Abrahamson M, Bj\u00f6rk I. Cystatin inhibition of cathepsin B requires dislocation of the proteinase occluding loop. Demonstration By release of loop anchoring through mutation of his110. Febs Lett. 2000;487:156\u201360.","journal-title":"Febs Lett"},{"key":"1544_CR41","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1080\/15548627.2020.1826716","volume":"17","author":"L Peintner","year":"2021","unstructured":"Peintner L, Venkatraman A, Waeldin A, Hofherr A, Busch T, Voronov A, et al. Loss of PKD1\/polycystin-1 impairs lysosomal activity in a CAPN (calpain)-dependent manner. Autophagy. 2021;17:2384\u2013400.","journal-title":"Autophagy"},{"key":"1544_CR42","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.bbadis.2012.09.011","volume":"1832","author":"GB Peres","year":"2013","unstructured":"Peres GB, Juliano MA, Sim\u00f5es MJ, Michelacci YM. Lysosomal enzymes are decreased in the kidney of diabetic rats. Biochim Biophys Acta. 2013;1832:85\u201395.","journal-title":"Biochim Biophys Acta"},{"key":"1544_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-1157-x","volume":"9","author":"R Qi","year":"2018","unstructured":"Qi R, Yang C. Renal tubular epithelial cells: the neglected mediator of tubulointerstitial fibrosis after injury. Cell Death Dis. 2018;9:1126.","journal-title":"Cell Death Dis"},{"key":"1544_CR44","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s10735-017-9720-9","volume":"48","author":"CA Romero","year":"2017","unstructured":"Romero CA, Remor A, Latini A, De Paul AL, Torres AI, Mukdsi JH. Uric acid activates NRLP3 inflammasome in an in-vivo model of epithelial to mesenchymal transition in the kidney. J Mol Histol. 2017;48:209\u201318.","journal-title":"J Mol Histol"},{"key":"1544_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bmc.2018.10.017","volume":"27","author":"J Schmitz","year":"2019","unstructured":"Schmitz J, Gilberg E, L\u00f6ser R, Bajorath J, Bartz U, G\u00fctschow M. Cathepsin B: active site mapping with peptidic substrates and inhibitors. Bioorg Med Chem. 2019;27:1\u201315.","journal-title":"Bioorg Med Chem"},{"key":"1544_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13727","volume":"7","author":"H Song","year":"2016","unstructured":"Song H, Liu B, Huai W, Yu Z, Wang W, Zhao J, et al. The E3 ubiquitin ligase TRIM31 attenuates NLRP3 inflammasome activation by promoting proteasomal degradation of NLRP3. Nat Commun. 2016;7:13727.","journal-title":"Nat Commun"},{"key":"1544_CR47","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1053\/j.ajkd.2017.08.017","volume":"71","author":"A Srivastava","year":"2018","unstructured":"Srivastava A, Kaze AD, McMullan CJ, Isakova T, Waikar SS. Uric acid and the risks of kidney failure and death in individuals with CKD. Am J Kidney Dis. 2018;71:362\u201370.","journal-title":"Am J Kidney Dis"},{"key":"1544_CR48","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/5817348","volume":"2020","author":"HY Su","year":"2020","unstructured":"Su HY, Yang C, Liang D, Liu HF. Research advances in the mechanisms of hyperuricemia-induced renal injury. Biomed Res Int. 2020;2020:5817348.","journal-title":"Biomed Res Int"},{"key":"1544_CR49","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41577-019-0165-0","volume":"19","author":"KV Swanson","year":"2019","unstructured":"Swanson KV, Deng M, Ting JP. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat Rev Immunol. 2019;19:477\u201389.","journal-title":"Nat Rev Immunol"},{"key":"1544_CR50","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.4049\/jimmunol.1201959","volume":"190","author":"W Wang","year":"2013","unstructured":"Wang W, Wang X, Chun J, Vilaysane A, Clark S, French G, et al. Inflammasome-independent NLRP3 augments TGF-\u03b2 signaling in kidney epithelium. J Immunol. 2013;190:1239\u201349.","journal-title":"J Immunol"},{"key":"1544_CR51","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.archger.2016.03.015","volume":"65","author":"N Wang","year":"2016","unstructured":"Wang N, Bai X, Jin B, Han W, Sun X, Chen X. The association of serum cathepsin B concentration with age-related cardiovascular-renal subclinical state in a healthy Chinese population. Arch Gerontol Geriatr. 2016;65:146\u201355.","journal-title":"Arch Gerontol Geriatr"},{"key":"1544_CR52","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1111\/tra.12613","volume":"19","author":"F Wang","year":"2018","unstructured":"Wang F, G\u00f3mez-Sintes R, Boya P. Lysosomal membrane permeabilization and cell death. Traffic. 2018;19:918\u201331.","journal-title":"Traffic"},{"key":"1544_CR53","first-page":"721","volume":"15","author":"CC Xu","year":"2017","unstructured":"Xu CC, Wang B, Pu YQ, Tao JS, Zhang T. Advances in extraction and analysis of phenolic compounds from plant materials. Chin J Nat Med. 2017;15:721\u201331.","journal-title":"Chin J Nat Med"},{"key":"1544_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42930-y","volume":"14","author":"LB Xu","year":"2023","unstructured":"Xu LB, Qin YF, Su L, Huang C, Xu Q, Zhang R, et al. Cathepsin-facilitated invasion of BMI1-high hepatocellular carcinoma cells drives bile duct tumor thrombi formation. Nat Commun. 2023;14:7033.","journal-title":"Nat Commun"},{"key":"1544_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2025.156507","volume":"139","author":"Q Yao","year":"2025","unstructured":"Yao Q, Zhang X, Wang L, Li J, Lv J, Chen J, et al. Therapeutic potential of p-coumaric acid in alleviating renal fibrosis through inhibition of M2 macrophage infiltration and cellular communication. Phytomedicine. 2025;139:156507.","journal-title":"Phytomedicine"},{"key":"1544_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117561","volume":"180","author":"C Zeng","year":"2024","unstructured":"Zeng C, Weng L, Song Y, Huang Y, Xiang W, Ye Z, et al. N-butanol extract of Broussonetia papyrifera (L.) L\u2019H\u00e9r. ex Vent root bark alleviates atopic dermatitis by targeting E3 ubiquitin ligase WWP1 to promote NLRP3 degradation. Biomed Pharmacother. 2024;180:117561.","journal-title":"Biomed Pharmacother"},{"key":"1544_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-022-00872-2","volume":"8","author":"S Zhang","year":"2022","unstructured":"Zhang S, Guan X, Liu W, Zhu Z, Jin H, Zhu Y, et al. YTHDF1 alleviates sepsis by upregulating WWP1 to induce NLRP3 ubiquitination and inhibit caspase-1-dependent pyroptosis. Cell Death Discov. 2022;8:244.","journal-title":"Cell Death Discov"}],"container-title":["Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10020-026-01544-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10020-026-01544-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10020-026-01544-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T01:02:32Z","timestamp":1789088552000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s10020-026-01544-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1544"],"URL":"https:\/\/doi.org\/10.1186\/s10020-026-01544-y","relation":{},"ISSN":["1528-3658"],"issn-type":[{"value":"1528-3658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]},"assertion":[{"value":"5 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal experiments were approved by the Ethics Committee of Shanghai Tongren Hospital, Shanghai Jiao Tong University School of Medicine (Approval Number: A2023-043\u201301) and were conducted in accordance with the National Institutes of Health\u2019s Guidelines for the Care and Use of Laboratory Animals. All studies involving human participants were carried out in accordance with the ethical standards of the World Medical Association Declaration of Helsinki. All clinical procedures were performed in compliance with relevant laws and institutional guidelines and were approved by the Ethics Committee of Shanghai Tongren Hospital, Shanghai Jiao Tong University School of Medicine (Approval Number: K2025-047\u201301). The privacy rights of all human subjects were strictly protected, and written informed consent was obtained from all patients prior to inclusion in the study.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"143"}}